A plain guide to the studies · Copper Tripeptide-1
GHK-Cu holds copper among three small protein pieces.
This page covers what the copper changes, what studies found, and where proof is still thin.

Copper makes GHK-Cu work differently
GHK-Cu is a short peptide that carries copper. Free GHK was found in blood in 1973.
Old liver tissue made younger-looking proteins when GHK was added [2]. That happened in a lab, not in a person.
Copper is the main difference between GHK-Cu and free GHK [2]. Their lab weights don't help you judge a skin product.
The name on a bottle tells you which form it holds. That matters when you match a bottle claim with its study.
In dishes, metalloproteinase-2—a protein that clears worn tissue—changed only with copper [7]. Free GHK left that protein unchanged.
The test used about one-billionth of a chemistry mole per liter or less, written as 10^-12 through 10^-11 M, with most near 10^-9 M [1]. Those dish amounts cannot set a human dose.
The cell count held steady. Collagen output rose in each cell.
Among women given GHK-Cu, 70% made more collagen. Vitamin C reached 50%; retinoic acid reached 40% [3].
A computer scan marked broad changes in gene activity [4]. The scan can't show help or harm in a person.
How long injected GHK-Cu stays in human blood remains unmeasured [6]. One team produced many early papers; outside checks remain scarce.
Benefits, Risks sets personal reports beside measured study results. The page keeps those kinds of proof apart.
GHK copper peptide comes from the body’s repair work
GHK has three protein parts and has drawn much study. The parts are called histidine, lysine, and glycine.
Those same parts occur in collagen and another large repair protein [6]. Scientists call the collagen part alpha-2(I), a label you needn't remember.
Injured tissue can release the short GHK piece. In dish work, such pieces spurred new vessel growth [8].
GHK-Cu holds one copper part and one peptide part, a 1:1 bond [2]. Lab tests show that bond is firm.
This firm hold may reduce harm caused by loose copper. It may also carry copper to working proteins.
A review reported gains in both collagen and elastin, which gives skin some spring [6]. A vessel-growth protein labeled FGF-2 also rose.
A scar-linked protein labeled tgf-beta-1 fell. Other changes supported nerves, cleared old tissue, and limited cell damage.
How copper peptides work explains those jobs. Copper tripeptide-1 covers label names, while GHK-Cu research findings sorts results by body part.
A copper peptide carries copper to working proteins
In these peptides, several linked protein parts cradle copper. The metal helps the short chain work.
GHK-Cu has the clearest research in this group. Copper helps one repair protein tie collagen and elastin together [6].
The links let tissue bear strain, then spring back. Copper also aids cell defenses against some damage.
One dish test changed MMP-2, a tissue-clearing protein, only when copper was present [7]. Free GHK left that protein unchanged.
That difference matters when you read a study. Evidence for either form doesn't carry over to the other.
GHK-Cu helps skin cells make repair material
GHK-Cu binds one copper ion to three small protein pieces. In lab dishes, it helped skin cells build collagen plus other material that supports skin [1][4].
The copper also changed proteins that clear and rebuild worn tissue. These findings explain a possible repair role, not a result promised to you.
Some women made more collagen after skin treatment
Skin studies found that GHK-Cu prompted skin cells to build collagen and other support material. Among treated women, one review counted a collagen rise in 70%, compared with 50% for vitamin C and 40% for retinoic acid [3].
Those results came from studies, not from a promise about your skin. The full GHK-Cu study page gives the fuller record.
Most GHK-Cu work is still in cells and animals
Human, animal, and dish studies have looked at GHK-Cu in wound repair. Reviews reported gains in collagen and elastin, plus vessel-growth protein FGF-2 [6].
A scar-linked protein labeled tgf-beta-1 fell, along with signs of cell damage. Most findings don't come from a large human trial.